Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI Town Hall report

Ashley M Fortress; Kiyoharu J Miyagishima; Amberlynn A Reed; Sally Temple; Dennis O Clegg; Budd A Tucker; Timothy A Blenkinsop; George Harb; Thomas N Greenwell; Tenneille E Ludwig; Kapil Bharti

doi:10.1186/s13287-023-03282-y

Back

Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI Town Hall report

Journal article

Open access

Peer reviewed

Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI Town Hall report

Ashley M Fortress, Kiyoharu J Miyagishima, Amberlynn A Reed, Sally Temple, Dennis O Clegg, Budd A Tucker, Timothy A Blenkinsop, George Harb, Thomas N Greenwell, Tenneille E Ludwig, …

Stem cell research & therapy, Vol.14(1), 53

03/29/2023

DOI: 10.1186/s13287-023-03282-y

PMCID: PMC10053463

PMID: 36978104

Files and links (1)

url

https://doi.org/10.1186/s13287-023-03282-yView

Published (Version of record) Open Access

Abstract

National Eye Institute recently issued a new Strategic Plan outlining priority research areas for the next 5 years. Starting cell source for deriving stem cell lines is as an area with gaps and opportunities for making progress in regenerative medicine, a key area of emphasis within the NEI Strategic Plan. There is a critical need to understand how starting cell source affects the cell therapy product and what specific manufacturing capabilities and quality control standards are required for autologous vs allogeneic stem cell sources. With the goal of addressing some of these questions, in discussion with the community-at-large, NEI hosted a Town Hall at the Association for Research in Vision and Ophthalmology annual meeting in May 2022. This session leveraged recent clinical advances in autologous and allogeneic RPE replacement strategies to develop guidance for upcoming cell therapies for photoreceptors, retinal ganglion cells, and other ocular cell types. Our focus on stem cell-based therapies for RPE underscores the relatively advanced stage of RPE cell therapies to patients with several ongoing clinical trials. Thus, this workshop encouraged lessons learned from the RPE field to help accelerate progress in developing stem cell-based therapies in other ocular tissues. This report provides a synthesis of the key points discussed at the Town Hall and highlights needs and opportunities in ocular regenerative medicine.

Cell- and Tissue-Based Therapy

Humans

Induced Pluripotent Stem Cells - metabolism

Pluripotent Stem Cells

Retinal Diseases - metabolism

Retinal Diseases - therapy

Retinal Pigment Epithelium - metabolism

Stem Cell Transplantation

Details

Title: Subtitle: Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI Town Hall report
Creators: Ashley M Fortress - National Eye Institute
Kiyoharu J Miyagishima - National Eye Institute
Amberlynn A Reed - National Eye Institute
Sally Temple - Neural Stem Cell Institute
Dennis O Clegg - University of California, Santa Barbara
Budd A Tucker - University of Iowa
Timothy A Blenkinsop - Icahn School of Medicine at Mount Sinai
George Harb - Biotech (Brazil)
Thomas N Greenwell - National Eye Institute
Tenneille E Ludwig - WiCell
Kapil Bharti - National Eye Institute
Resource Type: Journal article
Publication Details: Stem cell research & therapy, Vol.14(1), 53
DOI: 10.1186/s13287-023-03282-y
PMID: 36978104
PMCID: PMC10053463
NLM abbreviation: Stem Cell Res Ther
eISSN: 1757-6512
Grant note: name: Division of Intramural Research, National Eye Institute
Language: English
Date published: 03/29/2023
Academic Unit: Ophthalmology and Visual Sciences
Record Identifier: 9984381026302771

Metrics

16 Record Views

12 Times Cited - Web of Science

See more details